---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-276060"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:21:25.474794+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kalaris Q3 net loss narrows to $11.9M; cash $77M; Phase 1a data on track for year-end

## Summary
- Phase 1a SAD trial initial clinical data (safety, efficacy, PK) expected by year end 2025.
- Phase 1b/2 MAD trial in nAMD enrolling up to 80 patients; initial data expected 2H 2026.
- Cash, cash equivalents and ST investments $77.0M as of Sept 30, 2025; expected to fund operations into 2027.
- R&D expense $9.1M (vs $36.0M in Q3 2024); net loss $11.9M (vs $38.1M).
- Selected KBI Biopharma as CDMO; hired CFO Matthew Gall; opened NJ headquarters.

## SEC filing metadata
- accession: 0001193125-25-276060
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/0001193125-25-276060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/d70447d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-276060
- JSON: https://secwatch.observer/filing/0001193125-25-276060.json
- Plain text: https://secwatch.observer/filing/0001193125-25-276060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.